Vertex Nav1.8 inhibitor meets in Phase II for pain due to small fiber neuropathy

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said on Dec. 18 that VX-150 met the primary endpoint in a Phase II trial to treat chronic pain caused by small fiber neuropathy.

The double-blind, international trial enrolled 89 patients to receive placebo or 1,250 mg oral VX-150 every 24 hours. On the primary endpoint, VX-150 significantly reduced pain as measured by the within-group change from baseline in the weekly average of daily pain intensity on an 11-point numeric rating scale (NRS) at week six (within-group change of 2.02 points, p<0.0001). The mean within-group change from baseline to week six for the placebo arm was 0.93 points...